ABSTRACT
Objective To investigate the mRNA and protein expression of GPX3 gene in non-small cell lung cancer (NSCLC) patients, and then discuss the clinical significance of GPX3 in NSCLC patients. Methods Reverse transcription-polymerase chain reaction (RT-PCR) and Western blot were used to detect the GPX3 mRNA and protein levels in NSCLC tissues and adjacent non-cancerous normal lung tissues from 60 patients undergoing surgical treatment. The correlation between the expression levels of GPX3 and clinicopathological features was analyzed. Results The relative expression value of GPX3 mRNA was higher in adjacent non-cancerous tissues than in non-small cell lung cancer tissue (P < 0.05). GPX3 mRNA expression was significantly correlated with TNM stage、differentiation and lymph node metastasis. The integral optical density value of GPX3 protein confirmed was lower in adjacent non-cancerous tissues than in non-small cell lung cancer tissues (P < 0.05). In additional, the expression of GPX3 was related to TNM stage and lymph node metastasis. Conclusion The expression of GPX3 gene may play an important role in the carcinogenesis and progression of NSCLC.
ABSTRACT
Objective To compare the clinical efficacy and safety of continuous subcutaneous insulin infusion (CSII) and multiple subcutaneous insulin injection (MSII) in elderly patients with severe type 2 diabetes.Methods Thirty-seven elderly patients with severe type 2 diabetes in the hospital intensive care unit (ICU) were divided into observation group (19 cases) and control group (18 cases) by random number table method.The observation group was treated with continuous subcutaneous insulin recombinant human insulin lispro injection,and control group was treated with recombinant human insulin lispro injection before meals and at bedtime routine insulin glargine subcutaneous injection.Two groups of patients and their families were given diabetes education.Changes in blood glucose,insulin dosage,blood glucose control standard time,rate of hypoglycemia and hospitalization time between 2 groups before and after treatment were compared.Results After treatment,fasting blood glucose in observation group was (7.2 ± 1.2) mmol/L,2 hour postprandial blood glucose was (9.4 ± 1.2) mmol/L,bedtime blood glucose was (9.4 ± 1.3) mmol/L; which in control group was (8.5 ± 3.0),(10.0 ± 2.4),(10.2 ± 2.4)mmol/L respectively.Fasting blood glucose,2 hour postprandial blood glucose and bedtime blood glucose significantly decreased after treatment in two groups,but there was significant difference between 2 groups (P ＜ 0.05).Blood glucose control standard time in observation group was (5.4 ± 2.5) d,insulin dosage was (43 ± 9) U/d,in control group was (12.8 ± 3.8) d,(55 ± 10) U/d respectively,and there was significant difference (P ＜ 0.05).Observation group had no hypoglycemia.Conclusion CSII for elderly patients with severe type 2 diabetes has better curative effect and security than MSII,and is more conducive to the control of blood glucose and the improvement of the condition.